Olodaterol

• Description:

  Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively) . Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis[1][2][3].

• Product Name Alternative:

  BI1744

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/Olodaterol.html

• Purity:

  99.85

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic; warming)

• Smiles:

  O=C1NC2=CC (O) =CC ([C@@H] (O) CNC (C) (C) CC3=CC=C (OC) C=C3) =C2OC1

• Molecular Formula:

  C21H26N2O5

• Molecular Weight:

  386.44

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Xing G, et al. Design, synthesis and biological evaluation of 8- (2-amino-1-hydroxyethyl) -6-hydroxy-1,4-benzoxazine-3 (4H) -one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2020;28 (1) :115178.|[2]Herrmann FE, et al. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol. 2017;174 (21) :3848-3864.|[3]Bouyssou T, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models [published correction appears in J Pharmacol Exp Ther. 2013 Jul;346 (1) :161]. J Pharmacol Exp Ther. 2010;334 (1) :53-62.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  β adrenergic receptor

• CAS Number:

  868049-49-4